Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer

Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer - Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012862

Enrollment

Registered

2014-01-16

Start date

2014-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmation of non small cell lung cancer 2) No prior therapy of EGFR-TKI 3) Administration of erlotinib is planned 4) EGFR gene mutation has been examined 5) Measurable lesions based on RECIST ver1.1 6) Aged 20 or more 7) Expected survival over 12 weeks 8) Adequate organ functions 9) Written informed consent

Exclusion criteria

Exclusion criteria: Patients with interstitial pneumonitis identified by chest X-ray

Design outcomes

Primary

Measure	Time frame
Correlation between erlotinib exposure and clinical response	—

Countries

Japan

Contacts

Public ContactKenmotsu Hirotsugu

Shizuoka cancer center Division of Thoracic Oncology

h.kenmotsu@scchr.jp(+81)055-989-5222

Outcome results